Developer docs
API playgroundTry for free, no card

Search company profiles

Crossbow Therapeutics

Full company profile

uuid00003xt

Namestring
Crossbow Therapeutics
Legal namestring
Crossbow Therapeutics, Inc.
Websiteurl
crossbowtx.com
Company typeenum
Private
Founded yearint
2023
Descriptiontext

Crossbow Therapeutics is a clinical-stage biotechnology company developing T-cell engager (TCE) immunotherapies that target intracellular cancer proteins presented as peptide-HLA complexes—a class of antigens inaccessible to conventional antibody drugs and existing TCEs that rely on cell-surface proteins. The company's proprietary T-Bolt™ platform combines TCR-mimetic antibody discovery with bispecific T-cell engager architecture, enabling precise targeting of tumor-specific pHLA complexes while maintaining antibody manufacturability.

The pipeline is anchored by CBX-250, a first-in-class bispecific TCE targeting the cathepsin G (CTSG) CG1 pHLA complex for relapsed/refractory AML, HR-MDS, and CMML, which entered a Phase 1 trial (CROSSCHECK-001, NCT06994676) in September 2025. The second program, CBX-663, is a TERT-targeting TCE with dual TERT-binding domains for solid tumor and hematologic malignancies, with an IND filing targeted for Q3 2026. Two earlier-stage programs (CBX-589, CBX-880) extend the pipeline. A strategic collaboration with MD Anderson Cancer Center provides target validation and binder discovery capabilities.

The company is pre-commercial and headquartered in Cambridge, Massachusetts, with revenue expected to derive from future pharmaceutical licensing, co-development deals, milestones, and royalties. It has raised over $157 million across a Series A ($80M, July 2023, led by MPM BioImpact and Pfizer Ventures) and a Series B ($77M, March 2026, co-led by Taiho Ventures and Arkin Bio Capital), with Eli Lilly, Polaris Partners, and BVF Partners as repeat investors and recent additions including Blood Cancer United's Therapy Acceleration Program.

Short descriptiontext

Crossbow Therapeutics is a clinical-stage Cambridge, MA biotech developing T-Bolt™ TCR-mimetic antibody T-cell engagers that target intracellular cancer antigens via peptide-HLA complexes, with lead programs CBX-250 (Phase 1 in AML/MDS) and CBX-663 (pre-IND, TERT-targeted) and revenue expected from future pharmaceutical licensing.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersCambridge, United States
HQ citystring
Cambridge
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
T-cell engager therapies, TCR-mimetic antibodies, cancer immunotherapy, bispecific antibodies, targeted oncology therapeutics
Industry1 code
PRIMARYHLAAAAAF
Bispecific & Multispecific Antibodies
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
NAICS code1 code
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Oncology Therapeutics
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Pharmaceutical Licensing and Co-development
TypeLicensing Royalties
Description

Pre-commercial biotech company generating revenue through licensing agreements, co-development partnerships, and milestone payments with pharmaceutical companies. Revenue will be generated from drug development milestones, regulatory approvals, and potential future product sales upon FDA approval.

crossbowtx.com
2Strategic Collaborations
TypeLicensing Royalties
Description

Revenue generated through strategic collaborations with academic institutions and pharmaceutical partners such as MD Anderson Cancer Center, where Crossbow licenses technologies and co-develops therapeutic candidates.

crossbowtx.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1T-Bolt™
Description

Proprietary TCR-mimetic antibody technology platform enabling targeting of intracellular cancer antigens for development of T-cell engager therapies.

crossbowtx.com
+1 more record
Core offering1 text field

Crossbow Therapeutics develops TCR-mimetic antibody T-cell engager (TCE) immunotherapies for cancer using its proprietary T-Bolt™ platform. The platform engineers bispecific antibodies that recognize intracellular cancer antigens displayed as peptide-HLA complexes on tumor cell surfaces, expanding the target universe beyond what conventional antibodies and existing TCEs can reach. Lead clinical-stage candidates include CBX-250 (cathepsin G-targeting TCE) and CBX-663 (TERT-targeting TCE), with multiple additional pipeline programs.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • CBX-250 demonstrated high tumor antigen selectivity and potent antileukemic activity in preclinical in vivo models
+3 more records
Product overview1 text field

Crossbow Therapeutics is developing T-Bolt™, a proprietary TCR-mimetic antibody technology platform that enables the development of T-cell engager (TCE) immunotherapies targeting intracellular cancer proteins. The company's lead product is CBX-250, a first-in-class TCE targeting Cathepsin G pHLA currently in Phase 1 trials for myeloid malignancies. CBX-663, a second TCE targeting TERT pHLA for solid and hematologic tumors, is advancing toward IND filing. Additional pipeline programs include CBX-589 (Cathepsin G target) and CBX-880 (undisclosed solid tumor target).

Product and service4 records
1CBX-250
CategoryOncology Biologic (T-cell Engager)
Description

First-in-class bispecific T-cell engager (TCE) targeting the cathepsin G (CTSG) peptide-HLA (pHLA) complex (HLA-A*02:01-restricted), abundantly expressed on leukemic cells but not on normal myeloid cells. In development for relapsed or refractory myeloid malignancies including acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (HR-MDS), chronic myelomonocytic leukemia (CMML), and chronic myeloid leukemia (CML). Currently in Phase 1 clinical trial (CROSSCHECK-001, NCT06994676).

2CBX-663
CategoryOncology Biologic (T-cell Engager)
Description

Bispecific T-cell engager targeting the telomerase reverse transcriptase (TERT) peptide-HLA complex (HLA-A*02:01-restricted TERT540 peptide). Contains two binding domains for TERT to enhance tumor cell engagement and immune activation. In development for multiple hematologic and solid tumors including squamous non-small cell lung cancer (sqNSCLC), head and neck squamous cell carcinoma (HNSCC), ovarian cancer, esophageal cancer, and others. TERT is expressed in up to 95% of cancers. IND filing projected for Q3 2026.

3CBX-589
CategoryOncology Biologic (T-cell Engager)
Description

Pipeline program also targeting the Cathepsin G peptide-HLA complex, in discovery/early development stage.

4CBX-880
CategoryOncology Biologic (T-cell Engager)
Description

Pipeline program with undisclosed target for solid tumor and hematologic malignancies, in discovery stage.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierFlagshipTypeStrategic or Co-development Partner
Description

Strategic collaboration for discovery and preclinical development of CBX-250. Gheath Alatrash, DO, PhD, and Jeffrey Molldrem, MD, led discovery and validation of the CTSG-derived peptide (CG1) via functional studies and mass spectrometry. MD Anderson's ORBIT platform within Therapeutics Discovery division developed the TCR-mimetic binder to the CG1 pHLA complex, which Crossbow licensed for development. Crossbow designed and is conducting the CROSSCHECK-001 clinical study.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Harpoon developed T-cell engagers (TriTAC platform) for oncology and was acquired by Merck in 2024. It serves as a direct historical peer for bispecific T-cell engager biotechs of similar stage and approach to Crossbow.

TypeDirect peer
Description

Immunocore is a commercial-stage biotech developing TCR-based immunotherapies for cancer and infectious disease, including the approved TCR therapeutic tebentafusp. It is the most directly comparable peer to Crossbow as both companies engineer TCR-based or TCR-mimetic molecules targeting peptide-HLA complexes for oncology.

TypeDirect peer
Description

Adaptimmune develops engineered TCR-T cell therapies for solid tumors, including the approved afami-cel. It is a direct peer in the TCR-based oncology space and competes for similar target classes and HLA-restricted indications as Crossbow's TCR-mimetic programs.

TypeDirect peer
Description

Immatics develops TCR-based immunotherapies and TCR-mimetic antibody products (e.g., ACTengine and TCER formats) targeting intracellular cancer antigens presented on HLA. Its bispecific TCER pipeline most closely mirrors Crossbow's T-Bolt™ T-cell engager approach.

TypeDirect peer
Description

Maverick developed conditionally active T-cell engagers (COBRA platform) for solid tumors and was acquired by Takeda. It is a direct peer to Crossbow in next-generation bispecific T-cell engager development for oncology.

TypeBroad incumbent
Description

Macrogenics develops bispecific antibodies and DART-platform T-cell engagers for oncology (e.g., vobramitamab duocarmazine). It is a broader incumbent operating in the same T-cell engager / bispecific antibody category as Crossbow.

TypeBroad incumbent
Description

Amgen commercializes Blincyto (blinatumomab), the leading BiTE-format bispecific T-cell engager, and operates broadly in oncology biologics. It is a broad incumbent setting the commercial and clinical benchmark against which Crossbow's T-cell engager programs will be evaluated.

TypeBroad incumbent
Description

Genmab is a leading bispecific antibody platform company behind the approved Epkinly (epcoritamab) and multiple DuoBody-based oncology programs. It is a broad incumbent in the bispecific antibody space that Crossbow competes within for partnerships and pipeline priority.

TypeBroad incumbent
Description

Regeneron has a deep bispecific antibody pipeline (e.g., linvoseltamab, odronextamab) and is a broad incumbent in antibody-based oncology therapeutics. It is comparable to Crossbow as a competitor and potential partner/strategic acquirer in the bispecific antibody space.

TypeEmerging player
Description

Cullinan Oncology is a clinical-stage biotech developing targeted oncology therapeutics including T-cell engager and immune-engager programs. It is an emerging player with overlapping modality focus to Crossbow's TCE pipeline.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles16 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors15 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Crossbow Therapeutics

Oncology Therapeuticscrossbowtx.com

Crossbow Therapeutics is a clinical-stage Cambridge, MA biotech developing T-Bolt™ TCR-mimetic antibody T-cell engagers that target intracellular cancer antigens via peptide-HLA complexes, with lead programs CBX-250 (Phase 1 in AML/MDS) and CBX-663 (pre-IND, TERT-targeted) and revenue expected from future pharmaceutical licensing.

What Crossbow Therapeutics does

Crossbow Therapeutics is a clinical-stage biotechnology company developing T-cell engager (TCE) immunotherapies that target intracellular cancer proteins presented as peptide-HLA complexes—a class of antigens inaccessible to conventional antibody drugs and existing TCEs that rely on cell-surface proteins. The company's proprietary T-Bolt™ platform combines TCR-mimetic antibody discovery with bispecific T-cell engager architecture, enabling precise targeting of tumor-specific pHLA complexes while maintaining antibody manufacturability.

The pipeline is anchored by CBX-250, a first-in-class bispecific TCE targeting the cathepsin G (CTSG) CG1 pHLA complex for relapsed/refractory AML, HR-MDS, and CMML, which entered a Phase 1 trial (CROSSCHECK-001, NCT06994676) in September 2025. The second program, CBX-663, is a TERT-targeting TCE with dual TERT-binding domains for solid tumor and hematologic malignancies, with an IND filing targeted for Q3 2026. Two earlier-stage programs (CBX-589, CBX-880) extend the pipeline. A strategic collaboration with MD Anderson Cancer Center provides target validation and binder discovery capabilities.

The company is pre-commercial and headquartered in Cambridge, Massachusetts, with revenue expected to derive from future pharmaceutical licensing, co-development deals, milestones, and royalties. It has raised over $157 million across a Series A ($80M, July 2023, led by MPM BioImpact and Pfizer Ventures) and a Series B ($77M, March 2026, co-led by Taiho Ventures and Arkin Bio Capital), with Eli Lilly, Polaris Partners, and BVF Partners as repeat investors and recent additions including Blood Cancer United's Therapy Acceleration Program.

Crossbow Therapeutics firmographics

Firmographics
Name
Crossbow Therapeutics
Legal name
Crossbow Therapeutics, Inc.
Website
https://crossbowtx.com
Company type
Private
Founded year
2023
Operating status
Operating
Headcount range
11–50 employees
Short description
Crossbow Therapeutics is a clinical-stage Cambridge, MA biotech developing T-Bolt™ TCR-mimetic antibody T-cell engagers that target intracellular cancer antigens via peptide-HLA complexes, with lead programs CBX-250 (Phase 1 in AML/MDS) and CBX-663 (pre-IND, TERT-targeted) and revenue expected from future pharmaceutical licensing.
Ownership category
akta.pro rank

Crossbow Therapeutics industry classification

Industry
Product category
Oncology Therapeutics
NAICS
Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAAAF
Bispecific & Multispecific Antibodies
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)

Keywords

  • T-cell engager therapies
  • TCR-mimetic antibodies
  • Cancer immunotherapy
  • Bispecific antibodies
  • Targeted oncology therapeutics

Where Crossbow Therapeutics is headquartered

Location

Headquarters

HQ city
Cambridge
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Crossbow Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Pharmaceutical Licensing and Co-development: Pre-commercial biotech company generating revenue through licensing agreements, co-development partnerships, and milestone payments with pharmaceutical companies. Revenue will be generated from drug development milestones, regulatory approvals, and potential future product sales upon FDA approval.
  2. Strategic Collaborations: Revenue generated through strategic collaborations with academic institutions and pharmaceutical partners such as MD Anderson Cancer Center, where Crossbow licenses technologies and co-develops therapeutic candidates.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Crossbow Therapeutics product offering

Product offering

Core offering

Crossbow Therapeutics develops TCR-mimetic antibody T-cell engager (TCE) immunotherapies for cancer using its proprietary T-Bolt™ platform. The platform engineers bispecific antibodies that recognize intracellular cancer antigens displayed as peptide-HLA complexes on tumor cell surfaces, expanding the target universe beyond what conventional antibodies and existing TCEs can reach. Lead clinical-stage candidates include CBX-250 (cathepsin G-targeting TCE) and CBX-663 (TERT-targeting TCE), with multiple additional pipeline programs.

Product overview

Crossbow Therapeutics is developing T-Bolt™, a proprietary TCR-mimetic antibody technology platform that enables the development of T-cell engager (TCE) immunotherapies targeting intracellular cancer proteins. The company's lead product is CBX-250, a first-in-class TCE targeting Cathepsin G pHLA currently in Phase 1 trials for myeloid malignancies. CBX-663, a second TCE targeting TERT pHLA for solid and hematologic tumors, is advancing toward IND filing. Additional pipeline programs include CBX-589 (Cathepsin G target) and CBX-880 (undisclosed solid tumor target).

Differentiator

Problem solved

Functional benefit

Brands

  • T-Bolt™: Proprietary TCR-mimetic antibody technology platform enabling targeting of intracellular cancer antigens for development of T-cell engager therapies.
  • CROSSCHECK-001

Products and services

  • CBX-250 First-in-class bispecific T-cell engager (TCE) targeting the cathepsin G (CTSG) peptide-HLA (pHLA) complex (HLA-A*02:01-restricted), abundantly expressed on leukemic cells but not on normal myeloid cells. In development for relapsed or refractory myeloid malignancies including acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (HR-MDS), chronic myelomonocytic leukemia (CMML), and chronic myeloid leukemia (CML). Currently in Phase 1 clinical trial (CROSSCHECK-001, NCT06994676).
  • CBX-663 Bispecific T-cell engager targeting the telomerase reverse transcriptase (TERT) peptide-HLA complex (HLA-A*02:01-restricted TERT540 peptide). Contains two binding domains for TERT to enhance tumor cell engagement and immune activation. In development for multiple hematologic and solid tumors including squamous non-small cell lung cancer (sqNSCLC), head and neck squamous cell carcinoma (HNSCC), ovarian cancer, esophageal cancer, and others. TERT is expressed in up to 95% of cancers. IND filing projected for Q3 2026.
  • CBX-589 Pipeline program also targeting the Cathepsin G peptide-HLA complex, in discovery/early development stage.
  • CBX-880 Pipeline program with undisclosed target for solid tumor and hematologic malignancies, in discovery stage.

Quantifiable outcome

  • CBX-250 demonstrated high tumor antigen selectivity and potent antileukemic activity in preclinical in vivo models
  • +3 more outcomes

Companies that use Crossbow Therapeutics

Customer profile

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Crossbow Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Crossbow Therapeutics partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • The University of Texas MD Anderson Cancer CenterflagshipStrategic or Co-development PartnerStrategic collaboration for discovery and preclinical development of CBX-250. Gheath Alatrash, DO, PhD, and Jeffrey Molldrem, MD, led discovery and validation of the CTSG-derived peptide (CG1) via functional studies and mass spectrometry. MD Anderson's ORBIT platform within Therapeutics Discovery division developed the TCR-mimetic binder to the CG1 pHLA complex, which Crossbow licensed for development. Crossbow designed and is conducting the CROSSCHECK-001 clinical study.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Crossbow Therapeutics competitors and assessment

Company assessment

Direct peers

  • Harpoon Therapeutics: Harpoon developed T-cell engagers (TriTAC platform) for oncology and was acquired by Merck in 2024. It serves as a direct historical peer for bispecific T-cell engager biotechs of similar stage and approach to Crossbow.
  • Immunocore: Immunocore is a commercial-stage biotech developing TCR-based immunotherapies for cancer and infectious disease, including the approved TCR therapeutic tebentafusp. It is the most directly comparable peer to Crossbow as both companies engineer TCR-based or TCR-mimetic molecules targeting peptide-HLA complexes for oncology.
  • Adaptimmune Therapeutics: Adaptimmune develops engineered TCR-T cell therapies for solid tumors, including the approved afami-cel. It is a direct peer in the TCR-based oncology space and competes for similar target classes and HLA-restricted indications as Crossbow's TCR-mimetic programs.
  • Immatics: Immatics develops TCR-based immunotherapies and TCR-mimetic antibody products (e.g., ACTengine and TCER formats) targeting intracellular cancer antigens presented on HLA. Its bispecific TCER pipeline most closely mirrors Crossbow's T-Bolt™ T-cell engager approach.
  • Maverick Therapeutics: Maverick developed conditionally active T-cell engagers (COBRA platform) for solid tumors and was acquired by Takeda. It is a direct peer to Crossbow in next-generation bispecific T-cell engager development for oncology.

Broad incumbents

  • Macrogenics: Macrogenics develops bispecific antibodies and DART-platform T-cell engagers for oncology (e.g., vobramitamab duocarmazine). It is a broader incumbent operating in the same T-cell engager / bispecific antibody category as Crossbow.
  • Amgen: Amgen commercializes Blincyto (blinatumomab), the leading BiTE-format bispecific T-cell engager, and operates broadly in oncology biologics. It is a broad incumbent setting the commercial and clinical benchmark against which Crossbow's T-cell engager programs will be evaluated.
  • Genmab: Genmab is a leading bispecific antibody platform company behind the approved Epkinly (epcoritamab) and multiple DuoBody-based oncology programs. It is a broad incumbent in the bispecific antibody space that Crossbow competes within for partnerships and pipeline priority.
  • Regeneron: Regeneron has a deep bispecific antibody pipeline (e.g., linvoseltamab, odronextamab) and is a broad incumbent in antibody-based oncology therapeutics. It is comparable to Crossbow as a competitor and potential partner/strategic acquirer in the bispecific antibody space.

Emerging players

  • Cullinan Oncology: Cullinan Oncology is a clinical-stage biotech developing targeted oncology therapeutics including T-cell engager and immune-engager programs. It is an emerging player with overlapping modality focus to Crossbow's TCE pipeline.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

Crossbow Therapeutics social profiles

Digital presence

Crossbow Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Crossbow Therapeutics leadership team

Management profile

Number of profiles

Profiles16 records

Crossbow Therapeutics funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors15 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Crossbow Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Crossbow Therapeutics

What does Crossbow Therapeutics do?

Crossbow Therapeutics develops TCR-mimetic antibody T-cell engager (TCE) immunotherapies for cancer using its proprietary T-Bolt™ platform. The platform engineers bispecific antibodies that recognize intracellular cancer antigens displayed as peptide-HLA complexes on tumor cell surfaces, expanding the target universe beyond what conventional antibodies and existing TCEs can reach. Lead clinical-stage candidates include CBX-250 (cathepsin G-targeting TCE) and CBX-663 (TERT-targeting TCE), with multiple additional pipeline programs.

Is Crossbow Therapeutics a public or private company?

Crossbow Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Crossbow Therapeutics founded?

Crossbow Therapeutics was founded in 2023. It employs 11 to 50 people.

Where is Crossbow Therapeutics based?

Crossbow Therapeutics is headquartered in Cambridge, United States, in the North America region.

How does Crossbow Therapeutics make money?

Two revenue lines are on record. Pharmaceutical Licensing and Co-development is the primary driver. The others are strategic Collaborations.

Who are Crossbow Therapeutics's main competitors?

Direct peers on record are Harpoon Therapeutics, Immunocore, Adaptimmune Therapeutics, Immatics and Maverick Therapeutics. Broad incumbents are Macrogenics, Amgen, Genmab and Regeneron. Cullinan Oncology is listed as an emerging player.

Does Crossbow Therapeutics have an API?

No public API is recorded for Crossbow Therapeutics.

What industry is Crossbow Therapeutics in?

Crossbow Therapeutics's product category is Oncology Therapeutics. Its primary akta.pro industry code is HLAAAAAF, Bispecific & Multispecific Antibodies. Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Pulse 2.0Crossbow Therapeutics Doses First Patient In Phase 1 Trial Of CBX-663 For Hematologic And Solid TumorsCrossbow Therapeutics dosed the first patient in the TelOscope-001 Phase 1 trial of CBX-663, a T-cell engager targeting telomerase reverse transcriptase (TERT) for hematologic and solid tumors. The open-label dose-escalation study assesses safety and clinical activity, with initial data expected by end of 2027.WowtaleCancer cell-targeting protein immunotherapy 'Crossbow' secures $77 million Series B investment.Crossbow Therapeutics raised $77 million in a Series B funding round co-led by Taiho Ventures and Arkin Bio Capital, with participation from multiple new and existing investors including Pfizer Ventures and Eli Lilly, bringing its total funding to over $157 million. The company is developing T-Bolt, an off-the-shelf TCR-mimetic antibody therapy that can target intracellular peptide-HLA complexes in cancer cells—a capability that existing antibody drugs and T-cell engagers lack due to their reliance on surface proteins. Lead pipeline candidates CBX-250 (for myeloid malignancies) and CBX-663 (targeting TERT across blood and solid tumors) are advancing through Phase 1 and pre-IND stages respectively, with clinical data for CBX-250 expected by end of 2026.pharmaphorumKidney biotech R1's $78m debut, and other biofinancingsMarch has seen a cluster of biotech financing rounds, with six companies raising between $40 million and $78 million for candidates spanning chronic kidney disease, cancer cell therapies, and autoimmune diseases. R1 Therapeutics emerged from stealth with a $77.5 million Series A for a pan-phosphate transporter inhibitor (AP306) licensed from China's Alebund Pharmaceuticals, Crossbow Therapeutics raised $77 million for T-cell engagers targeting myeloid cancers, and Excalipoint Therapeutics secured $68.7 million for a trispecific cancer antibody. Additional rounds included Prolium Bioscience's $50 million Series A for an autoimmune TCE, Unnatural Products' $45 million Series B for macrocyclic peptide development, Vima Therapeutics' expansion to $100 million Series A for a movement disorder candidate, and Mestag Therapeutics' $40 million for a bispecific antibody heading to Phase 1 trials.The Pharma LetterCrossbow Therapeutics raises $77 million in Series B financingCrossbow Therapeutics raised $77 million in a Series B financing round. The funds will support the completion of the CROSSCHECK-001 Phase I trial of its lead program CBX-250 and accelerate development of additional T-Bolt immunotherapies.FinSMEsCrossbow Therapeutics Raises $77M in Series B FundingCrossbow Therapeutics, a Cambridge-based biotechnology company developing antibody therapies for cancer, raised $77M in Series B funding led by Taiho Ventures and Arkin Bio Capital, with participation from multiple investors including Pfizer Ventures, Eli Lilly, and others. As part of the financing, representatives from Taiho Ventures and Arkin Bio Capital joined the company's Board of Directors. The company intends to use the funds to expand its operations and advance its T-cell engager (TCE) therapy pipeline targeting cancer cells.Business Wire BlogCrossbow Therapeutics Raises $77 Million in Series B Financing to Advance Development of TCR-mimetic Antibody Therapies to Treat CancerCrossbow Therapeutics, a biotechnology company developing TCR-mimetic antibody therapies for cancer, raised $77 million in Series B financing co-led by Taiho Ventures and Arkin Bio Capital. The funding will support completion of the CROSSCHECK-001 Phase 1 clinical trial for CBX-250 in myeloid malignancies and advance the Phase 1 trial for CBX-663 targeting hematologic and solid tumors, with initial data for CBX-250 expected around the end of 2026.FierceBiotechCrossbow hits $77M series B round to bankroll quiver of T-BoltsCrossbow Therapeutics has secured a $77 million Series B funding round co-led by Taiho Ventures and Arkin Bio Capital, with participation from returning investors Eli Lilly and Pfizer Ventures, to fund clinical trials of its T-cell engager pipeline including lead asset CBX-250. The biotech will advance its ongoing Phase 1 trial in acute myeloid leukemia and other myeloid malignancies with a data readout expected at the end of 2026, while also preparing a second TCE candidate (CBX-663) for hematologic and solid tumor trials scheduled to begin in Q3. The company, incubated at MPM BioImpact and launched in 2023 with an $80 million Series A, is led by former AstraZeneca chief medical officer Briggs Morrison.Venture Capital Access OnlineCrossbow Therapeutics Raises $77 Million in Series B Financing to Advance Development of TCR-mimetic Antibody Therapies to Treat CancerCrossbow Therapeutics raised $77 million in Series B financing co-led by Taiho Ventures and Arkin Bio Capital to advance its T-Bolt™ TCR-mimetic antibody therapies for cancer treatment. The funding will support completion of the CROSSCHECK-001 Phase 1 clinical trial of CBX-250 in myeloid malignancies and enable submission of an Investigational New Drug application for CBX-663 with a Phase 1 trial initiation projected for Q3 2026. Initial clinical data from the CBX-250 trial is expected around the end of 2026.CrossbowtxMarch 18, 2026Crossbow Therapeutics has raised $77 million in Series B financing co-led by Taiho Ventures and Arkin Bio Capital to advance its T-Bolt™ TCR-mimetic antibody therapies for cancer treatment. The funding will support completion of the CROSSCHECK-001 Phase 1 trial of lead program CBX-250 in myeloid malignancies and enable submission of an IND application for CBX-663 to treat hematologic and solid tumors, with initial clinical data expected around the end of 2026.BioPharma DiveCrossbow raises $77M for new cancer immunotherapiesCrossbow Therapeutics announced it raised $77 million in a Series B round to advance its lead cancer drug CBX-250 through clinical development. The company is developing next-generation T cell engagers that aim to minimize immune-related side effects common with existing approved therapies, and is currently recruiting patients for a Phase 1 trial with early data expected by the end of 2026. The financing was co-led by Taiho Ventures and Arkin BioCapital, with participation from 11 other investors including Pfizer Ventures and Polaris Partners.